Noble Life Sciences, a contract research organization (CRO) providing services to support the development of drugs, vaccines, and medical devices, is pleased to announce that it has been granted a renewal of full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International Council on Accreditation. Noble was first awarded AAALAC full accreditation in October 10, 1989.
The renewal, which was granted after an extensive on-site assessment and review of the Noble Life Sciences animal care and use program by the AAALAC International Council on Accreditation, comes without any recommendations for improvement from AAALAC International. Accredited organizations are re-evaluated every three years.
“The Council recognizes your efforts to achieve a quality animal care and use program and commends you and your staff for the positive actions taken” noted Andrew Grady, Council President-Pro Tem in a letter to Noble.
“We are very proud to be granted renewal of our full accreditation status. It affirms the dedication of our staff to highest standards of animal care and validates our commitment to industry and regulatory guidelines,” said Srujana Cherukuri, CEO of Noble Life Sciences. “AAALAC accreditation is a voluntary process by which our program and our staff undergo intense scrutiny, but we see it as a critical part of our assessment program.”
AAALAC International is a private, nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. More than 980 companies, universities, hospitals, government agencies and other research institutions in 44 countries have earned AAALAC accreditation, demonstrating their commitment to responsible animal care and use. These institutions volunteer to participate in AAALAC's program, in addition to complying with the local, state and federal laws that regulate animal research.
About Noble Life Sciences
Noble Life Sciences is a preclinical contract research organization offering GLP and non-GLP services, in both large and small animals, for the development of drugs, vaccines, and medical devices. Preclinical development services include PK and PD studies; biodistribution studies; immunization and immunogenicity testing; early safety assessments; reproductive and developmental toxicity testing; surgical services; medical device protocol development and testing; analytical and imaging services; and preclinical formulation development. Our services also include the derivation and maintenance of animal breeding colonies, animal housing and husbandry, the development of disease and animal models, and the production of custom antibodies and are backed by AAALAC accreditation, OLAW assurance, a USDA license and over 50 years of experience. For more information about Noble Life Sciences, visit www.noblelifesci.com.